Kenneth Duncan

Company: Accent Therapeutics

Job title: SVP, Chemistry

Seminars:

RNA-Modifying Enzyme Inhibitors as Synthetic Lethal Cancer Therapeutics 4:30 pm

Expanding the potential impact of helicase inhibitors beyond MSI-H cancers with DHX9-targeted therapeutics Validation and drug discovery enablement of RNA modifying nuclease target XRN1 in tumors with elevated interferon signalingRead more

day: Day One